Forum: Articles of Interest
11-04-2006, 05:29 AM
|
|
Replies: 6
Views: 1,992
and more...
About Attenuon
Attenuon is a San Diego-based clinical-stage biopharmaceutical company developing a
new generation of cancer therapeutics. Attenuon’s compounds – two of which are
currently...
|
|
Forum: Articles of Interest
11-04-2006, 05:28 AM
|
|
Replies: 6
Views: 1,992
more...
“We believe that the uPA system is a promising target for inhibiting tumor growth,
metastasis, and angiogenesis,” said Josh Distler, Attenuon’s chief operating officer. “We
are very...
|
|
Forum: Articles of Interest
11-04-2006, 05:27 AM
|
|
Replies: 6
Views: 1,992
|
|
Forum: Articles of Interest
11-04-2006, 04:40 AM
|
|
Replies: 6
Views: 1,992
Your right on the mark
I did not add that to the post--because I don't like to keep posting things which remind everyone that herceptin works in in the minority of patients (usually quoted as around 40%) it is given to. ...
|
|
Forum: Articles of Interest
11-03-2006, 10:53 AM
|
|
Replies: 6
Views: 1,992
abstract
Overexpression of urokinase plasminogen activator system or HER-2 (erbB-2) in breast cancer is associated with a poor prognosis. HER-2 overexpression is caused by HER-2 gene amplification. The...
|
|
Forum: Articles of Interest
11-03-2006, 10:52 AM
|
|
Replies: 6
Views: 1,992
|
